Clinical Trial: A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

U.S., Aug. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07767903) titled 'A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder' on Aug. 11.

Brief Summary: This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day [mg/day]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).

Study Start Date: Aug. 07

Study Type: INTERVENTIONAL

Condition: Generalized Anxiety Disorder

Intervention: DRUG: SEP-363856

Oral tablet

DRUG: Placebo

O...